Evolus announces expansion into US dermal filler market with Evolysse
Evolus, Inc., the aesthetic neurotoxin company, has announced it has entered into a definitive agreement to be the exclusive US distributor of a line of five new dermal fillers, made by the French company Symatese. The dermal fillers are currently in late-stage development.
The addition of a filler line expands the company’s total addressable US market by 70%, by adding a $1.6 billion (£1.3 billion) US filler market prospect to the existing $2.3 billion (£1.8 billion) aesthetic neurotoxin market opportunity provided by Evolus’ flagship product, Jeuveau (prabotulinumtoxinA-xvfs). Both the filler and aesthetic neurotoxin markets are expected to nearly double by 2028.
“Today’s announcement represents a material step in achieving our goal of transforming Evolus into a multi-product aesthetics company,” said the president and chief executive officer of Evolus, David Moatazedi. “We are excited to expand our portfolio with Evolysse, a highly competitive filler line that complements our fast-growing aesthetic neurotoxin, Jeuveau. Injectables are the cornerstone of aesthetics with neurotoxins and dermal fillers the top two aesthetic procedures in the US Our customer-centric approach, existing digital infrastructure and distribution platform will power the launch of this innovative filler technology into the hands of our customers and their patients.”
“We are honoured to partner with Symatese to introduce the Evolysse line to our US customers, beginning with the expected launch of the first two indications in the first half of 2025, followed by a third in 2026 and two more in 2027,” continued Moatazedi. “Once fully launched, the Evolysse portfolio will offer a complete range of filler solutions to cover the spectrum of indications including mid-face, nasolabial folds, lips and eyes.
Symatese is a privately-held French company that designs and manufactures regenerative medical solutions, with vast expertise in hyaluronic acid and injection systems. It is well-known for the development of the latest generation of Restylane products in the United States based on XpresHAn Technology/OBT.
“For the last 25 years, Symatese has had a rich history in developing numerous products for aesthetic and therapeutic purposes,” said the chief executive of Symatese, Jean-Paul Gérardin. “We are particularly excited to partner with Evolus in bringing our next-generation HA filler product line to the US. This innovative technology, which is supported by a robust global clinical development program, is based on a pioneering, gentler crosslinking technology that better preserves hyaluronic acid chains and aims to improve product performance and safety for the benefit of practitioners and their patients.”
In consideration of the exclusive US distribution rights, Evolus will pay Symatese a total of €16.2 million (£14.1 million), including an upfront payment of €4.1 million (£3.6 million) and €12.1 million (£10.5 million) of additional payments beginning in June 2025. Evolus will also pay Symatese a mid-single-digit royalty based on net sales and a product transfer price, while the companies will share responsibility for expenses related to the registration of the two planned product launches in 2027. The initial agreement is for a term of 15 years, with automatic five-year renewal provisions.
Assuming the Evolysse product line launches as planned, Evolus expects to achieve $200 million (£160 million) in incremental annual sales by 2028. The 2028 revenue expectation for the organic growth of Jeuveau to $500 million (£400 million) remains unchanged. As such, the company is raising its 2028 revenue outlook to $700 million (£559 million).
“From a financial standpoint, this long-term partnership is highly capital efficient and expected to be gross margin and operating income accretive at scale,” revealed Moatazedi. “Using the available $50 million (£40 million) tranche of our credit facility with Pharmakon Advisors we are funding our agreement obligations and expecting to carry Evolus to profitability in 2025. This transaction expands our product portfolio with a differentiated filler product line and we gain access to a large and growing market estimated to nearly double in size by 2028.”
For more information, visit evolus.com and symatese.com
